vs
BioNexus Gene Lab Corp（BGLC）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是BioNexus Gene Lab Corp的290.7倍（$140.6M vs $483.8K）。VERACYTE, INC.净利率更高（29.3% vs -214.2%，领先243.4%）。VERACYTE, INC.同比增速更快（18.5% vs -80.8%）。VERACYTE, INC.自由现金流更多（$48.8M vs $960.1K）。过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs -54.9%）
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
BGLC vs VCYT — 直观对比
营收规模更大
VCYT
是对方的290.7倍
$483.8K
营收增速更快
VCYT
高出99.4%
-80.8%
净利率更高
VCYT
高出243.4%
-214.2%
自由现金流更多
VCYT
多$47.8M
$960.1K
两年增速更快
VCYT
近两年复合增速
-54.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $483.8K | $140.6M |
| 净利润 | $-1.0M | $41.1M |
| 毛利率 | -0.8% | 72.5% |
| 营业利润率 | -213.5% | 26.4% |
| 净利率 | -214.2% | 29.3% |
| 营收同比 | -80.8% | 18.5% |
| 净利润同比 | -197.5% | 704.8% |
| 每股收益（稀释后） | — | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGLCVCYT
| Q4 25 | $483.8K | $140.6M | ||
| Q3 25 | $2.5M | $131.9M | ||
| Q2 25 | $2.3M | $130.2M | ||
| Q1 25 | $2.1M | $114.5M | ||
| Q4 24 | $2.5M | $118.6M | ||
| Q3 24 | $2.6M | $115.9M | ||
| Q2 24 | $2.0M | $114.4M | ||
| Q1 24 | $2.4M | $96.8M |
净利润BGLCVCYT
| Q4 25 | $-1.0M | $41.1M | ||
| Q3 25 | $-709.0K | $19.1M | ||
| Q2 25 | $-616.2K | $-980.0K | ||
| Q1 25 | $-623.3K | $7.0M | ||
| Q4 24 | $-348.3K | $5.1M | ||
| Q3 24 | $-1.3M | $15.2M | ||
| Q2 24 | $199.1K | $5.7M | ||
| Q1 24 | $-103.8K | $-1.9M |
毛利率BGLCVCYT
| Q4 25 | -0.8% | 72.5% | ||
| Q3 25 | 14.8% | 69.2% | ||
| Q2 25 | 16.3% | 69.0% | ||
| Q1 25 | 16.1% | 69.5% | ||
| Q4 24 | 12.3% | 66.4% | ||
| Q3 24 | 12.4% | 68.2% | ||
| Q2 24 | 14.6% | 68.1% | ||
| Q1 24 | 15.3% | 64.5% |
营业利润率BGLCVCYT
| Q4 25 | -213.5% | 26.4% | ||
| Q3 25 | -27.6% | 17.4% | ||
| Q2 25 | -27.0% | -4.0% | ||
| Q1 25 | -28.9% | 2.5% | ||
| Q4 24 | -16.5% | 3.5% | ||
| Q3 24 | -50.9% | 10.4% | ||
| Q2 24 | 13.1% | 4.0% | ||
| Q1 24 | -3.3% | -4.8% |
净利率BGLCVCYT
| Q4 25 | -214.2% | 29.3% | ||
| Q3 25 | -27.9% | 14.5% | ||
| Q2 25 | -27.3% | -0.8% | ||
| Q1 25 | -29.2% | 6.2% | ||
| Q4 24 | -13.8% | 4.3% | ||
| Q3 24 | -51.1% | 13.1% | ||
| Q2 24 | 10.1% | 5.0% | ||
| Q1 24 | -4.4% | -1.9% |
每股收益（稀释后）BGLCVCYT
| Q4 25 | — | $0.50 | ||
| Q3 25 | $-0.40 | $0.24 | ||
| Q2 25 | $-0.34 | $-0.01 | ||
| Q1 25 | $-0.04 | $0.09 | ||
| Q4 24 | $0.55 | $0.07 | ||
| Q3 24 | $-0.75 | $0.19 | ||
| Q2 24 | $0.11 | $0.07 | ||
| Q1 24 | $-0.01 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $362.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.6M | $1.3B |
| 总资产 | $9.3M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BGLCVCYT
| Q4 25 | $2.5M | $362.6M | ||
| Q3 25 | — | $315.6M | ||
| Q2 25 | — | $219.5M | ||
| Q1 25 | — | $186.1M | ||
| Q4 24 | $2.9M | $239.1M | ||
| Q3 24 | — | $274.1M | ||
| Q2 24 | — | $235.9M | ||
| Q1 24 | — | $209.2M |
股东权益BGLCVCYT
| Q4 25 | $8.6M | $1.3B | ||
| Q3 25 | $6.8M | $1.3B | ||
| Q2 25 | $7.5M | $1.2B | ||
| Q1 25 | $7.8M | $1.2B | ||
| Q4 24 | $8.3M | $1.2B | ||
| Q3 24 | $9.4M | $1.2B | ||
| Q2 24 | $9.5M | $1.1B | ||
| Q1 24 | $9.3M | $1.1B |
总资产BGLCVCYT
| Q4 25 | $9.3M | $1.4B | ||
| Q3 25 | $7.6M | $1.4B | ||
| Q2 25 | $9.4M | $1.3B | ||
| Q1 25 | $9.5M | $1.3B | ||
| Q4 24 | $10.4M | $1.3B | ||
| Q3 24 | $11.0M | $1.3B | ||
| Q2 24 | $11.1M | $1.2B | ||
| Q1 24 | $11.2M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $961.1K | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $960.1K | $48.8M |
| 自由现金流率自由现金流/营收 | 198.5% | 34.7% |
| 资本支出强度资本支出/营收 | 0.2% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $-1.9M | $126.6M |
8季度趋势，按日历期对齐
经营现金流BGLCVCYT
| Q4 25 | $961.1K | $52.6M | ||
| Q3 25 | $-1.2M | $44.8M | ||
| Q2 25 | $-737.9K | $33.6M | ||
| Q1 25 | $-824.1K | $5.4M | ||
| Q4 24 | $219.2K | $24.5M | ||
| Q3 24 | $-1.6M | $30.0M | ||
| Q2 24 | $-672.3K | $29.6M | ||
| Q1 24 | $-37.2K | $-9.0M |
自由现金流BGLCVCYT
| Q4 25 | $960.1K | $48.8M | ||
| Q3 25 | $-1.2M | $42.0M | ||
| Q2 25 | $-759.4K | $32.3M | ||
| Q1 25 | $-833.1K | $3.5M | ||
| Q4 24 | $215.2K | $20.4M | ||
| Q3 24 | $-1.8M | $27.7M | ||
| Q2 24 | $-674.1K | $26.8M | ||
| Q1 24 | $-59.1K | $-11.1M |
自由现金流率BGLCVCYT
| Q4 25 | 198.5% | 34.7% | ||
| Q3 25 | -48.9% | 31.8% | ||
| Q2 25 | -33.6% | 24.8% | ||
| Q1 25 | -39.0% | 3.1% | ||
| Q4 24 | 8.5% | 17.2% | ||
| Q3 24 | -68.5% | 23.9% | ||
| Q2 24 | -34.1% | 23.4% | ||
| Q1 24 | -2.5% | -11.5% |
资本支出强度BGLCVCYT
| Q4 25 | 0.2% | 2.7% | ||
| Q3 25 | 0.2% | 2.1% | ||
| Q2 25 | 0.9% | 1.0% | ||
| Q1 25 | 0.4% | 1.6% | ||
| Q4 24 | 0.2% | 3.5% | ||
| Q3 24 | 7.6% | 1.9% | ||
| Q2 24 | 0.1% | 2.4% | ||
| Q1 24 | 0.9% | 2.2% |
现金转化率BGLCVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | -3.38× | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGLC
暂无分部数据
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
